DURHAM – The privately-held, Durham-headquartered Entegrion has raised more than $13.8 million in new equity funding, according to an SEC filing.

The company, which according to its website is “dedicated to providing innovative solutions to improve clinicians’ ability to effectivenly manage hemostasis in patients,” raised this round of funding from 83 investors.

And more could be coming, as the filing notes a total offering amount of $20 million.  Prior funding rounds for the company, as noted in the SEC database, included amended filings in 2016, 2017, and 2019.

Among the company’s partners and clients is the United States Department of Defense, a major funding partner for the company to advance its blood coagulation technologies.  According to the company’s website, the Department of Defense has awarded more than $100 million to the company in product development contracts, including $7.8 million in 2014.

That includes the latest product under development, which the company calls Resusix®.  According to the company, this is “a dehydrated, pooled, pathogen reduced plasma, as a safe alternative to FFP, without dependence on cold chain storage.”

The company also offers a viscoelastic coagulation monitor, known as VCM™, that provides “rapid, real-time hemostasis assessment at the point-of-care,” according to the company’s website.  This system is cleared for use in Europe, but not yet in the United States, the company’s website notes.

A clinical trial result, announced by the company in 2021, was said by the company to successfully demonstrate the clinical value of using heel stick samples run on the portable viscoelastic coagulation monitor in newborn babies. It has a CE mark for use in Europe.

Durham life sciences firm earns praise for tech to monitor premature newborns’ blood

For working capital

The SEC filing notes that the proceeds of the fundraising effort will be used for working capital, and that some of the funding may be used as “normal compensation to executive officers.”

Entegrion spun out of the University of North Carolina at Chapel Hill in 2002 as Hemocellular Therapeutics before changing names.

The North Carolina Biotechnology Center awarded the company a $150,000 Small Business Research Loan in 2003, according to a prior report published on WRAL TechWire.

Albert Valada, the company’s president and CEO, signed the filing.